National Cancer Institute
National Cancer Institute U.S. National Institutes of Health

Myeloma Steering Committee

The NCI Myeloma Steering Committee (MYSC) was established in 2009. Members of the MYSC include Cooperative Group myeloma committee chairs, representatives from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN), and investigators from Specialized Programs of Research Excellence (SPORE), Cancer Centers and R01/P01 grants along with community oncologists, biostatisticians, patient advocates and NCI staff.

Mission Statement

The MYSC follows an efficient, cost-effective, science-driven, and transparent process to identify and promote the "Best Science" in clinical research on myeloma and related diseases by addressing the design and prioritization of phase III trials and large phase II studies.

Roster of Myeloma Steering Committee (MYSC) members
Morie Gertz, MD, and Nikhil Munshi, MD, Co-chairs

Clinical Trial Planning Meetings (CTPMs): Goal of Clinical Trial Planning Meetings, and List of CTPM Executive Summaries and Publications

CCCT Contact: Lawrence Baizer, Ph.D.